AbbVie

AbbVie Reports Surge in New Drug Sales Offsetting Humira's Decline

2 months ago

In a significant financial update, AbbVie Inc. has announced that its recent introduction of new medications is helping to mitigate the revenue losses resulting from the declining sales of its blockbuster drug, Humira. As a leader in the biopharmaceutical industry, AbbVie is navigating a pivotal transformation as it evolves beyond Humira, a drug that has been a cornerstone of its revenue for years.

AbbVie’s New Schizophrenia Drug Suffers Major Setback in Clinical Trials

5 months ago

AbbVie, the biopharmaceutical giant known for its innovative drug portfolio, has experienced a significant downturn following disappointing results from two large-scale clinical trials of its investigational drug for schizophrenia. This development has sent ripples through the pharmaceutical sector, resulting in a substantial drop in the company’s stock price.

AbbVie Raises Profit Outlook as Rinvoq and Skyrizi Outperform Expectations

5 months ago

In a significant update from the biopharmaceutical giant AbbVie, the company has revised its profit expectations upward following strong performance from its inflammatory drugs, Rinvoq and Skyrizi. This development, reported on October 30, 2024, signals a promising trend in AbbVie's growth strategy and showcases the resilience of its product pipeline amidst a competitive market landscape.